Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 95INDUSTRY 65NIH 4NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Axitinib × Clear all
NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting
720 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02164838 2018-01-29

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
51 enrolled
Other solid neoplasm

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡